SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as its high-performance, compliance-first Layer 1 network, validated at over 11 million transactions per second, integrates a live fiat anchor with Bridge, a Stripe company. This partnership enables seamless, regulated movements of traditional currencies and stablecoins, positioning KTA as crucial financial plumbing for institutional adoption in global payments. The community is actively discussing KTA's significant potential and perceived undervaluation, viewing it as an asymmetric opportunity in the evolving digital finance landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending after receiving FDA approval for YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, with commercial launch set for January. The community is buzzing with optimism, anticipating a massive short squeeze and significant undervaluation given the drug's market potential and the company's strategic partnership with Novo Nordisk. Discussion centers on the long-term holding prospects and potential for a buyout, despite some debate on near-term volatility.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is a major topic after its drug Aqvesme (mitapivat) secured FDA approval as the only therapy for alpha- and beta-thalassemia, tapping into a significant patient population. While this milestone is driving considerable optimism and discussions of upward potential within the community, some investors are weighing its label, which includes a Risk Evaluation and Mitigation Strategy (REMS), against the stock's recent price movements. This approval marks a key moment, particularly after earlier mixed results from a different clinical program.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending due to positive news on significant regulatory relief, including the lifting of a key consent order, alongside a strong earnings report that reinforced confidence in its ongoing transformation strategy. The community is actively debating if the stock's remarkable appreciation, which has seen it reach multi-year highs, is sustainable amidst discussions of overbought technical levels, despite a broader optimistic outlook for the financial sector.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as its depression drug candidate failed to meet the primary endpoint in a Phase 2 trial, prompting the company to shift its focus away from psychiatric indications. The community is discussing this latest setback, with many investors now pinning their hopes on the accelerated immunology, obesity, and epilepsy programs, particularly the highly anticipated epilepsy trial, as crucial future catalysts for a potential turnaround.

Sprott Physical Platinum and Palladium Trust - Unit

Sprott Physical Platinum & Palladium

Sprott Physical Platinum & Palladium is gaining significant attention following robust price appreciation, fueled by critical industrial demand for uses like catalytic converters and electronics. Community discussion highlights the metals' under-owned status and supply risks from key producing nations, prompting expectations of a continued breakout as investors seek diversification. Many see potential for Platinum to reclaim its historical premium over gold.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is currently a major talking point following the announcement that Sanofi has agreed to acquire the company for $15.50 per share, a deal valued at approximately $2.2 billion to expand Sanofi's adult immunization offerings. While many investors are celebrating the long-awaited exit and the premium offered, a significant portion of the community expresses strong disappointment, arguing the acquisition price notably undervalues Dynavax's Hepatitis B vaccine and promising shingles pipeline.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc

iRhythm Technologies is generating significant buzz following a flurry of bullish analyst upgrades and compelling AMALFI study data that validates the superior performance of its Zio service for AFib detection. The community is actively discussing this strong fundamental and institutional interest, which appears to be outweighing recent bearish sentiment, highlighting the company's innovation in the digital cardiac monitoring space. This momentum is further supported by recent positive earnings and strategic operational advancements, positioning IRTC as a key player in healthcare technology.

Dycom Industries, Inc. provides contracting services throughout the United States. Its services include engineering, construction, maintenance and installation services to telecommunications providers, underground facility locating services to various utilities, including other construction and maintenance services to electric and gas utilities, and others. The company was founded in 1969 and is headquartered in West Palm Beach, FL.

Dycom Industries, Inc.

Dycom Industries is experiencing significant momentum following its strategic acquisition of Power Solutions, bolstering its capabilities in digital infrastructure and data center construction for AI-driven demand. The community is bullish on the company's strong earnings and record backlog, highlighting its prime position to capitalize on extensive fiber deployment and BEAD program funding, which has led to widespread analyst upgrades and optimistic market sentiment.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is a focal point of discussion following the launch of its Grayscale ETF and the active integration of its CCIP with global financial systems for real-world asset tokenization. The community is actively debating its long-term value as a foundational oracle network, with strong proponents highlighting institutional adoption against those frustrated by its price movements. This discussion is further fueled by conversations about complementary, high-throughput settlement infrastructure. 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

twitter

$70,000 - $80,000

$80,001 - $90,000

$90,001 - $100,000

Other (Comment Below)

Bitcoin has seen massive volatility this quarter as ETFs, macro conditions, and crypto adoption continue to shape price action. As 2025 comes to a close, where do you think Bitcoin ($BTC) will finish on December 31, 2025 (EST)?

Where Will Bitcoin Close on Dec 31, 2025?

NYKO
NIYOKO by Virtuals

Chart

News

Sentiment

Info

Historical Prices

Poll

Latest NYKO News

NYKONIYOKO by Virtuals